Vendor Intelligence Report: AKS Chem

Executive summary

Across 1 Finnrick lab test, AKS Chem’s overall pass rate is 100% (1 pass / 0 fail). That sounds clean, but the record is narrow: the only Finnrick-backed product is tirzepatide, where the single pass makes AKS Chem more defensible than its untested peptide listings. It does not establish lot-to-lot consistency or support projecting confidence onto retatrutide, semaglutide, cagrilintide, or the rest of the catalog.

The corporate diligence is sharper than the assay count. Registry records tie AKS Chem/AKSCHEM to Zibo Accesscn International Trading Co., Ltd., a Chinese company controlled by Di Yangping; those records support a wholesale chemical-trader profile, not a verified GMP peptide manufacturer. Marketplace claims of close to 30 years of peptide-rooted history and GMP/API production are materially stronger than the public registry and documentation trail.

Several authenticity and buyer-leverage signals need context before a GLP-1 order. The branded domain redirects into a CEINFO platform subdomain, the investigated product page returned a gateway timeout, and the TLS setup served a certificate for a different domain. The Made-in-China review surface also shows five identical 5-star reviews, while the visible promotion scan found no affiliate-code network and no meaningful English-language community reputation base.

For buyers, the practical read is product-specific: AKS Chem is a narrow tirzepatide candidate only if the shipped lot is independently verified, while untested GLP-1 listings require stricter proof. The report also maps customs and payment exposure, including non-green-list GLP-1 import-alert context and reshipment language that may reduce loss but increases border-interaction risk.

Inside the full report:

• CNVerify registry extract mapping Zibo Accesscn, Di Yangping, formation records, address, capital, and wholesale classification
• Claims-verification analysis of the 30-year history, GMP/API language, BV audit badge, and retatrutide COA provenance
• Digital-infrastructure findings for akschem.com, accesscn.cezibo.com, the gateway outage, and the TLS certificate mismatch
• Per-product Finnrick data, methodology-divergence charts, and Appendix A laboratory table for the single tested product
• Made-in-China review-manipulation exhibit plus community, coupon, Reddit, X, and affiliate-promotion sweep
• GLP-1 import-alert, customs-reshipment, shipping, payment, and material risk-matrix analysis

Risk assessment

• Misleading corporate and manufacturing claims — high: Made-in-China history and GMP/API production claims are unsupported by records showing a 2016 wholesale chemical trader, not a verified peptide manufacturer.
• Marketplace review manipulation risk — high: Made-in-China displays five identical 5-star reviews using boilerplate text, so the public rating should not be treated as genuine buyer reputation.
• GLP-1 import and customs-reshipment risk — high: Tirzepatide, semaglutide and retatrutide face non-green-list Import Alert 66-80 exposure; cagrilintide sits in the same customs-reship weight-loss catalog.
• Unverified quality controls for untested peptides — high: Retatrutide, semaglutide and cagrilintide have no Finnrick AKS Chem data; the reviewed retatrutide COA uses an in-house standard and no named third-party lab.
• Single-test confidence risk for tirzepatide — medium: Tirzepatide has one Finnrick pass and a 79.84% rating, but no repeat AKS Chem tests to show lot-to-lot consistency.
• Website and TLS infrastructure risk — medium: The primary accesscn.cezibo.com product page returned HTTP 504 and the investigated TLS served a mismatched test-grade certificate, weakening authenticity and data-submission trust.
• Payment and seizure-remedy risk — medium: Observed T/T and L/C terms offer limited chargeback-style protection in a GLP-1 shipping model that anticipates customs detention and reshipment.